Controlled drug delivery from composites of nanostructured porous silicon and poly(L-lactide)

Nanomedicine

Volumn 7, Issue 7, 2012, Pages 995-1016

  McInnes, Steven J P ^a   Irani, Yazad ^a   Williams, Keryn A ^a   Voelcker, Nicolas H ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

composite material; glaucoma; localized drug delivery; poly(L lactide); porous silicon; uveitis

Indexed keywords

CAMPTOTHECIN; POLYLACTIC ACID; POROUS SILICON; SILICON; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC FORCE MICROSCOPY; CHEMICAL ANALYSIS; CONTACT ANGLE; CYTOTOXICITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; FLUOROMETRY; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; POLYMERIZATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; HUMANS; NANOCOMPOSITES; NANOTECHNOLOGY; POLYESTERS; POROSITY; SILICON;

EID: 84864441469     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.176     Document Type: Article

References (91)

1. Castro G, Panilaitis B, Kaplan D. Emulsan, a tailorable biopolymer for controlled release. Bioresour. Technol. 99(11), 4566-4571 (2008). (Pubitemid 351503805)
2. Hughes G. Nanostructure-mediated drug delivery. Nanomed. Nanotechnol. Biol. Med. 1(1), 22-30 (2005). (Pubitemid 43963612)
3. Peng P, Kumar S, Voelcker NH, Szili E, Smart RSC, Griesser HJ. Thin calcium phosphate coatings on titanium by electrochemical deposition in modifed simulated body fuid. J. Biomed. Mater. Res. Part A 76, 347-355 (2006).
4. Batra I, Coffer J, Canham L. Electronically-responsive delivery from a calcifed mesoporous silicon structure. Biomed. Microdevices 8, 93-97 (2006). (Pubitemid 44251362)
5. Bikram M, Gobin A, Whitmire R, West J. Temperature-sensitive hydrogels with SiO-Au nanoshells for controlled drug delivery J. Control. Release 123, 219-227 (2007). (Pubitemid 350007822)
6. He J, Chen J-Y, Wang P et al. Poly(N-isopropylacrylamide)-coated thermo-responsive nanoparticles for controlled delivery of sulfonated Zn-phthalocyanine in Chinese hamster ovary cells in vitro and zebra fsh in vivo. Nanotechnology 18(41), 415101 (2007).
7. Koh Y, Jang S, Kim J et al. DBR pSi/PMMA composite materials for smart patch application. Colloids Surf. A 313-314, 328-331 (2008).
8. Lin M, Wang H, Meng S et al. Structure and release behavior of PMMA/silica composite drug delivery system. J. Pharm. Sci. 96(6), 1518-1526 (2007). (Pubitemid 46953767)
9. Song SW, Hidajat K, Kawi S. pH-Controllable drug release using hydrogel encapsulated mesoporous silica. Chem. Commun. 42, 4396-4398 (2007). (Pubitemid 351223606)
10. Andreadis S, Geer D. Biomimetic approaches to protein and gene delivery for tissue regeneration. Trends Biotechnol. 24(7), 331-337 (2006). (Pubitemid 43975575)
11. Elvira C, Gallardo A, San Roman J, Cifuentes A. Covalent polymer-drug conjugates. Molecules 10, 114-125 (2005). (Pubitemid 40404890)
12. Sharma S, Jasper Nijdam A, Sinha P et al. Controlled-release microchips. Expert Opin. Drug Deliv. 3(3), 379-394 (2006). (Pubitemid 43772713)
13. Soppimath K, Aminabhavi T, Kulkarni A, Rudzinski W. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70(1-2), 1-20 (2001). (Pubitemid 32144788)
14. Wood K, Boedicker J, Lynn D, Hammond P. Tunable drug release from hydrolytically degradable layer-by-layer thin flms. Langmuir 21(4), 1603-1609 (2005). (Pubitemid 40275101)
15. Tsukagoshi T, Kondo Y, Yoshino N. Preparation of thin polymer flms with controlled drug release. Colloids Surf. B 57(2), 219-225 (2007). (Pubitemid 46660570)
16. Smith JR, Smith RD, Holland GN et al. Differential effcacy of tumor necrosis factor inhibition in the management of infammatory eye disease and associated rheumatic disease. Arthritis Care Res. 45, 252-257 (2001). (Pubitemid 32952905)
17. Jabs DA, Rosenbaum JT, Foster CS et al. Guidelines for the use of immunosuppressive drugs in patients with ocular infammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol. 130(4), 492-513 (2000).
18. Jap A, Chee S-P. Immunosuppressive therapy for ocular diseases. Curr. Opin. Ophthalmol. 19, 535-540 (2008).
19. Leske MC. Open-angle glaucoma: an epidemiologic overview. Ophthal. Epidemiol. 14, 166-172 (2007).
20. Rolim De Moura CR, Paranhos A Jr, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Rev. 4, CD003919 (2009).
21. Vass C, Hirn C, Sycha T et al. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Rev. 4, CD003167 (2009).
22. Chang J-H, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr. Opin. Ophthalmol. 12, 242-249 (2001). (Pubitemid 32751680)
23. Canham LT. Bioactive silicon structure fabrication through nanoetching techniques. Adv. Mater. 7(12), 1033-1037 (1995).
24. Canham L, Aston R. Will a chip everyday keep the doctor away? Phys. World 14, 27-31 (2001). (Pubitemid 33763223)
25. Properties of Porous Silicon. Canhan L (Ed.). Short Run Press, London, UK (1997).
26. Park J-H, Gu L, Maltzahn GV, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat. Mater. 8, 331-336 (2009).
27. Schwartz M, Cunin F, Cheung R, Sailor M. Chemical modifcation of silicon surfaces for biological applications. Phys. Status Solid. A 202(8), 1380-1384 (2005). (Pubitemid 41364964)
28. Letant S, Kane S, Hart B et al. Hydrolysis of acetylcholinesterase inhibitors-organophosphorous acid anhydrase enzyme immobilization on photoluminescent porous silicon platforms. Chem. Commun. 7, 851-853 (2005). (Pubitemid 40313252)
29. Thomas J, Pacholski C, Sailor M. Delivery of nanogram payloads using magnetic porous silicon microcarriers. Lab Chip 6, 782-787 (2006). (Pubitemid 43847314)
30. Anglin E, Schwartz M, Ng V, Perelman L, Sailor M. Engineering the chemistry and nanostructure of porous silicon Fabry-Perot flms for loading and release of a steroid. Langmuir 20(25), 11264-11269 (2004).
31. Anglin E, Cheng L, Freeman W, Sailor M. Porous silicon in drug delivery devices and materials. Adv. Drug Deliv. Rev. 60, 1266-1277 (2008).
32. McInnes SJP, Voelcker NH. Silicon-polymer hybrid materials for drug delivery Future Med. Chem. 1(6), 1051-1074 (2009).
33. Prestidge C, Barnes T, Lau C-H, Barnett C, Loni A, Canham L. Mesoporous silicon: a platform for the delivery of therapeutics. Expert Opin. Drug Deliv. 4(2), 101-110 (2007). (Pubitemid 46389909)
34. Cheng L, Anglin E, Cunin F et al. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug delivery vehicle. Br. J. Opthalmol. 92, 705-711 (2008). (Pubitemid 351684186)
35. Dorvee J, Derfus A, Bhatia S, Sailor M. Manipulation of liquid droplets using amphiphilic, magnetic one-dimensional photonic crystal chaperones. Nat. Mater. 3, 896-899 (2004).
36. Low S, Williams K, Canham L, Voelcker N. Evaluation of mammalian cell adhesion on surface-modifed porous silicon. Biomaterials 27(26), 4538-4546 (2006). (Pubitemid 43783226)
37. Low SP, Voelcker NH, Canham LT, Williams KA. The biocompatibility of porous silicon in tissues of the eye. Biomaterials 30, 2873-2880 (2009).
38. McInnes SJP, Thissen H, Choudhury N, Voelcker N. New biodegradable materials produced by ring opening polymerisation of poly(L-lactide) on porous silicon substrates. J. Colloid Interface Sci. 332(2), 336-344 (2009).
39. Maretschek S, Greiner A, Kissel T. Electrospun biodegradable nanofber nonwovens for controlled release of proteins. J. Control. Release 127, 180-187 (2008).
40. Mundargi RC, Srirangarajan S, Agnihotri SA et al. Development and evaluation of novel biodegradable microspheres based on poly(D,L-lactide-co- glycolide) and poly(ε-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies. J. Control. Release 119, 59-68 (2007). (Pubitemid 46561539)
41. Youxin L, Volland C, Kissel T. In vitro degradation and bovine serum albumin release of the ABA triblock copolymers consisting of poly (L(+) lactic acid), or poly (L(+) lactic acid-co-glycolic acid) A-blocks attached to central polyoxyethylene B-blocks. J. Control. Release 32, 121-128 (1994).
42. Robert L. New methods of drug delivery Science 249, 1527-1533 (1990).
43. Choi I, Langer R. Surface-initiated polymerization of L-lactide: coating of solid substrates with a biodegradable polymer. Macromolecules 34, 5361-5363 (2001). (Pubitemid 34217235)
44. Kowalski A, Duda A, Penczek S. Kinetics and mechanism of cyclic esters polymerization initiated with tin (II) octoate. 3: polymerization of L,L-dilactide. Macromolecules 33, 7359-7370 (2000).
45. Langer R. Biomaterials in drug delivery and tissue engineering: one laboratory's experience. Acc. Chem. Res 33, 94-101 (2000).
46. Lee W, Lee J, Ha C. Growth of monolayered poly(L-lactide) lamellar crystals on a substrate. Macromol. Res. 11(6), 511-513 (2003). (Pubitemid 38482190)
47. Panyam J, Labhasetwar V Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol. Pharmaceutics 1(1), 77-84 (2004).
48. Tasaka F, Ohya Y, Ouchi T. Synthesis of novel comb-type polylactide and its biodegradability. Macromolecules 34, 5494-5500 (2001). (Pubitemid 34217252)
49. Yoon K, Koh Y, Choi I et al. Surface-initiated, ring-opening polymerisation of p-dioxanone from gold and silicon oxide surfaces. J. Mater. Chem 13, 2910-2914 (2003).
50. Albertsson A, Varma I. Recent developments in ring opening polymerisation of lactones for biomedical applications. Biomacromolecules 4, 1466-1486 (2003). (Pubitemid 37460959)
51. Andreopoulos A, Hatzi E, Doxastakis M. Controlled release of salicylic acid from poly(D,L-lactide). J. Mater. Sci. Mater. Med. 12, 233-239 (2001). (Pubitemid 32207078)
52. Lehninger A, Nelson D, Cox M. Principles of Biochemistry. Worth Publishers, NY, USA (1993).
53. Zhang Y, Chu C. Biodegradable dextran-polylactide hydrogel networks: their swelling, morphology and the controlled release of indomethacin. Biomed. Mater. Res. 59, 318-328 (2002). (Pubitemid 33126637)
54. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475-2490 (2000).
55. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem. Rev. 99, 3181-3198 (1999). (Pubitemid 129583051)
56. Dong WY, Körber M, Esguerra VL, Bodmeier R. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. J. Control. Release 115, 158-167 (2006). (Pubitemid 44537494)
57. Cheng L, Anglin E, Cunin F et al. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle. Br. J. Opthalmol. 92(5), 705-711 (2008). (Pubitemid 351684186)
58. Armarego W, Perrin D. Purifcation of Laboratory Chemicals, 4th Edition. Butterworth-Heinemann, Oxford, UK (1996).
59. Zhao X, Zu Y, Li Q et al. Preparation and characterization of camptothecin powder micronized by a supercritical antisolvent (SAS) process. J. Supercritical Fluids 51, 412-419 (2010).
60. Sigma-Aldrich. (S)-(+)-Camptothecin material Safety Data Sheet. Sigma-Aldrich Pty. Ltd. Castle Hill, NSW, Australia (2010).
61. Sætern AM, Nguyen NB, Bauer-Brandl A, Brandl M. Effect of hydroxypropyl-cyclodextrin-complexation and pH on solubility of camptothecin. Int. J. Pharm. 284, 61-68 (2004).
62. Basak SC, Kumar KS, Ramalingam M. Design and release characteristics of sustained release tablet containing metformin HCl. Braz. J. Pharm. Sci. 44(3), (2008).
63. Bhattacharyya S, Ray S, Gupta BK, Ghosh LK. Design, evaluation and statistical optimisation of a controlled release multiparticulate acyclovir delivery system. Lat. Am. J. Pharm. 26(6), 852-858 (2007). (Pubitemid 351316666)
64. Dave BS, Amin AF, Patel MM. Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS PharmSci. Tech. 5(2), e34 (2004).
65. Naeem M, Mahmood A, Khan S, Shahiq Z. Development and evaluation of controlled-release bilayer tablets containing microencapsulated tramadol and acetaminophen. Trop. J. Pharm. Res. 9(4), 347-354 (2010).
66. ® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. Int. J. Nanomed. 6, 151-166 (2011).
67. Poovi G, Lekshmi UD, Narayanan N, Reedy P. Preparation and characterisation of repaglinide loaded chitosan polymeric nanoparticles. Res. J. Nanosci. Nanotechnol. 1(1), 12-24 (2011).
68. Ravi PR, Ganga S, Saha RN. Design and study of lamivudine oral controlled release tablets. AAPS PharmSci. Tech. 8(4), E101 (2007).
69. 2 and mesoporous SBA-15. Colloids Surf. A 287, 51-58 (2006). (Pubitemid 44764796)
70. Meaurio E, Lopez-Rodriguez N, Sarasua Jr. Infrared spectrum of poly(L-lactide): application to crystallinity studies. Macromolecules 39, 9291-9301 (2006). (Pubitemid 46102004)
71. Dubois P, Jacobs C, Jerome R, Teyssie P. Macromolecular engineering of polylactones and polylactides. 4: Mechanism and kinetics of lactide homopolymerization by aluminum isopropoxide. Macromolecules 24, 2266-2270 (1991).
72. Goffn A-L, Duquesne E, Moins S, Alexandre M, Dubois P. New organic-inorganic nanohybrids via ring opening polymerization of (di)lactones initiated by functionalized polyhedral oligomeric silsesquioxane. Eur. Polym. J. 43, 4103-4113 (2007). (Pubitemid 47483722)
73. Cam D, Marucci M. Infuence of residual monomers and metals on poly(L-lactide) thermal stability. Polymer 38(8), 1879-1884 (1997). (Pubitemid 127410995)
74. Fleurya F, Kudelinab I, Nabieva I. Interactions of lactone, carboxylate and self-aggregated forms of camptothecin with human and bovine serum albumins. FEBS Letters 406, 151-156 (1997).
75. Wall ME, Wani MC, Cook CE, Palmer KH, Mcphail AT, Sim GA. Plant anti-tumor agents. I. The isolation and structure of campthothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptohtheca acuminata. J. Am. Chem. Soc. 88(16), 3888-3890 (1966).
76. Kanga J, Kumara V, Yanga D, Chowdhurya PR, Hohlb RJ. Cyclodextrin complexation: infuence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur. J. Pharm. Sci. 15, 163-170 (2002).
77. Abraham LM, Selva D, Casson R, Leibovitch I. Mitomycin: clinical applications in ophthalmic practice. Drugs 66(3), 321-340 (2006). (Pubitemid 46291768)
78. Li Y, Cunin F, Link J et al. Polymer replicas of photonic porous silicon for sensing and drug delivery applications. Science 299, 2045-2047 (2003). (Pubitemid 36383727)
79. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharmaceutica Drug Res. 67(3), 217-233 (2010).
80. Higuchi T. Rate of release of medicaments from ointment based containing drugs in suspension. J. Pharm. Sci. 50, 847 (1961).
81. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 52(12), 1145 (1963).
82. Hixson A, Crowell J. Dependence of reaction velocity upon surface and agitation. Ind. Eng. Chem. 23(8), 923-931 (1931).
83. Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Control. Release 5, 37-42 (1987). (Pubitemid 17106644)
84. Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Release 5, 23-36 (1987). (Pubitemid 17106643)
85. Desai SJ, Simonelli A P, Higuchi WI. Investigation of factors infuencing release of solid drug dispersed in inert matrices. J. Pharm. Sci. 54, 1459-1464 (1965).
86. Desai SJ, Singh P, Simonelli AP, Higuchi WI. Investigation of factors infuencing release of solid drug dispersed in inert matrices II. J. Pharm. Sci. 55, 1224-1229 (1966).
87. Andersson J, Rosenholm J, Areva S, Linden M. Infuences of material characteristics on ibuprofen drug loading and release profles from ordered micro-and mesoporous silica matrices. Chem. Mater. 16, 4160-4167 (2004).
88. Shoaib MH, Tazeen J, Merchant HA, Yousuf RI. Evaluation of drug release kinetics from ibuprofen matrix release tablets using HPMC. Pak. J. Pharm. Sci. 19(2), 119-124 (2006).
89. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. Acta Helv. 60(4), 110-111 (1985).
90. Peel MR, Milstead MW, Sternbach DD et al. Novel A-ring modifed camptothecins as topoisomerase I inhibitors. Bioorganic Med. Chem. Lett. 5(18), 2129-2132 (1995).
91. Yang F, Xu C, Kotaki M, S. W, Ramakrishna S. Characterisation of neutral stem cells on electrospun poly(L-lactic acid) nanofbrous scaffold. J. Biomater. Sci. Polymer Ed. 15(12), 1483-1497 (2004). (Pubitemid 40045376)